Insmed Incorporated (INSM)

In October 2025, Insmed reported its third-quarter financial results, with BRINSUPRI generating $28.1 million and ARIKAYCE $114.3 million in revenue, and raised its 2025 global ARIKAYCE revenue guidance. In November 2025, the European Commission approved BRINSUPRI for NCFB. In December 2025, inducement awards were granted to 92 new employees. In January 2026, Insmed reported strong preliminary full-year 2025 revenue results, with BRINSUPRI sales of $144.6 million and ARIKAYCE exceeding guidance with $433.8 million, and provided 2026 guidance, including at least $1 billion for BRINSUPRI; CEO William Lewis sold 19,215 shares. In February 2026, Insmed reported fourth-quarter and full-year 2025 financial results, reiterating strong revenue guidance for BRINSUPRI and ARIKAYCE for 2026. In March 2026, positive topline results were announced from the Phase 3b ENCORE study of ARIKAYCE, and COO Roger Adsett sold 88,060 shares. In April 2026, a clinical update on the Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa (HS) was provided, announcing that the study did not meet its primary or secondary efficacy endpoints, leading to the discontinuation of the HS program, which led to a stock sell-off and a trading halt; CEO William Lewis also reported exercising stock options and selling shares.

The available information does not explicitly indicate significant demand seasonality for Insmed's commercial products, ARIKAYCE and BRINSUPRI. The demand for these therapies appears to be driven by the ongoing medical need for treating chronic and rare lung diseases.

Insmed, Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, particularly pulmonary and inflammatory conditions. The company's major commercial products include ARIKAYCE, an inhaled antibiotic for Mycobacterium avium complex (MAC) lung disease, and BRINSUPRI, an oral inhibitor for non-cystic fibrosis bronchiectasis (NCFB). Insmed also has a pipeline of investigational medicines and drug discovery programs, including Treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH), INS1148 for respiratory and immunological and inflammatory diseases, and early-stage gene therapy candidates such as INS1201, INS1202 and INS1203.

Insmed is headquartered in Bridgewater, New Jersey, USA, and maintains offices and research locations across the United States, Europe (Utrecht, Netherlands; Zug, Switzerland; UK), and Japan. Its significant subsidiaries are primarily located in Europe and North America.

Insmed's brand reputation has been shaped by its clinical advancements and commercial performance. The company is recognized as a "people-first global biopharmaceutical company" and has been acknowledged as one of the best employers in the biopharmaceutical industry. The FDA approval and successful U.S. launch of BRINSUPRI, followed by European approval, significantly boosted the company's market reputation. Consistent double-digit growth and strong sales performance of ARIKAYCE globally have reinforced its reputation. Positive topline results from the Phase 3b ENCORE study for ARIKAYCE further enhanced its scientific and clinical reputation. The discontinuation of the brensocatib program for hidradenitis suppurativa could be perceived as a setback, but some analysts view this as having a minor impact.

Insmed's ownership is predominantly held by institutional investors, who collectively hold a substantial portion of the company's stock, ranging from approximately 64.89% to 84.11%. Major institutional owners include Jpmorgan Chase & Co, Vanguard Group Inc., Darwin Global Management, Ltd., BlackRock, Inc., Fmr Llc, Baker Bros. Advisors Lp, State Street Corp, Capital International Investors, Artisan Partners Limited Partnership and Rtw Investments, Lp. Insiders, including executives, hold a smaller but significant stake, around 0.76% of the company's stock.